“Off-the-shelf” cellular medicine resubmitted to the FDA
Mesoblast has resubmitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). Survival outcomes have not improved over the past two decades for the most severe… Read More